BioMarin: Genzyme virus problem won

oryzacody.wordpress.com
Genzyme (NASDAQ: GENZ) founx a virus strain and stopped production of two drugs atthe Mass., facility. The strain, Vesivirus 2117, apparentlyg does not cause human infection but interrupts the growtu of cells that are used to make Aldurazyme — a treatment for MPS I, a rare and fatall disease caused by an enzyme deficiency — was last fillef at the Genzyme facility in September 2008, according to BioMarin (NASDAQ: BMRN). The compan has about 10 months of vialefd inventoryon hand, it said, and uses a secondx fill finish supplier.
A third supplier is expected to be qualifiedc laterthis year, BioMarin BioMarin makes the bulk material used in Aldurazymse at its Novato The Food and Drug Administration had inspected Genzyme’ s plant in September and October and reportedly was concernesd about controls to protect against contamination.